際際滷shows by User: pavithravinayak / http://www.slideshare.net/images/logo.gif 際際滷shows by User: pavithravinayak / Wed, 12 Aug 2020 12:04:47 GMT 際際滷Share feed for 際際滷shows by User: pavithravinayak Mesurement of GFR and creatinine clearence /slideshow/mesurement-of-gfr-and-creatinine-clearence/237781500 pavi-gfrestimation-200812120447
measurement of GFR and creatinine clearence-- design of dosage for hepatic patients -- therapeutic drug monitoring and clinical pharmacokinetics fifth pharm D notes ]]>
measurement of GFR and creatinine clearence-- design of dosage for hepatic patients -- therapeutic drug monitoring and clinical pharmacokinetics fifth pharm D notes ]]> Wed, 12 Aug 2020 12:04:47 GMT /slideshow/mesurement-of-gfr-and-creatinine-clearence/237781500 pavithravinayak@slideshare.net(pavithravinayak) Mesurement of GFR and creatinine clearence pavithravinayak measurement of GFR and creatinine clearence-- design of dosage for hepatic patients -- therapeutic drug monitoring and clinical pharmacokinetics fifth pharm D notes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pavi-gfrestimation-200812120447-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> measurement of GFR and creatinine clearence-- design of dosage for hepatic patients -- therapeutic drug monitoring and clinical pharmacokinetics fifth pharm D notes
Mesurement of GFR and creatinine clearence from pavithra vinayak
]]> 5927 0 https://cdn.slidesharecdn.com/ss_thumbnails/pavi-gfrestimation-200812120447-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Effect of liver disease on pharmacokinetics /slideshow/effect-of-liver-disease-on-pharmacokinetics/237781348 pavi-effectofliverdiseaseonpkfactors-200812115918
Effect of liver disease on pharmacokinetics --dosage adjustment in hepatic patients therapeutic drug monitoring and clinical pharmacokinetics]]>
Effect of liver disease on pharmacokinetics --dosage adjustment in hepatic patients therapeutic drug monitoring and clinical pharmacokinetics]]> Wed, 12 Aug 2020 11:59:18 GMT /slideshow/effect-of-liver-disease-on-pharmacokinetics/237781348 pavithravinayak@slideshare.net(pavithravinayak) Effect of liver disease on pharmacokinetics pavithravinayak Effect of liver disease on pharmacokinetics --dosage adjustment in hepatic patients therapeutic drug monitoring and clinical pharmacokinetics <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pavi-effectofliverdiseaseonpkfactors-200812115918-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Effect of liver disease on pharmacokinetics --dosage adjustment in hepatic patients therapeutic drug monitoring and clinical pharmacokinetics
Effect of liver disease on pharmacokinetics from pavithra vinayak
]]> 3114 0 https://cdn.slidesharecdn.com/ss_thumbnails/pavi-effectofliverdiseaseonpkfactors-200812115918-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Genetic polymorphism in drug transport and drug targets. /slideshow/genetic-polymorphism-in-drug-transport-and-drug-targets/237780983 pavi-drugtransportandtargets-200812114336
Genetic polymorphism in drug transport and targets.--pharmacogenetics DRUG TRANSPORTER Two types of transporter : ATP binding Cassette (ABC) Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer. Solute Carrier (SLC) Transport varieties of solute include both charged or uncharged P-glycoprotein ATP binding cassette subfamily B member- 1 (ABCB 1) Multidrug resistance protein 1 (MDR1) Transport various molecules, including xenobiotic, across cell membrane Extensively distributed and expressed throughout the body Mechanism of Pglycoprotein Substrate bind to P-gp form the inner leaflet of the membrane ATP binds at the inner side of the protein ATP is hydrolyzed to produce ADP and energy ]]>
Genetic polymorphism in drug transport and targets.--pharmacogenetics DRUG TRANSPORTER Two types of transporter : ATP binding Cassette (ABC) Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer. Solute Carrier (SLC) Transport varieties of solute include both charged or uncharged P-glycoprotein ATP binding cassette subfamily B member- 1 (ABCB 1) Multidrug resistance protein 1 (MDR1) Transport various molecules, including xenobiotic, across cell membrane Extensively distributed and expressed throughout the body Mechanism of Pglycoprotein Substrate bind to P-gp form the inner leaflet of the membrane ATP binds at the inner side of the protein ATP is hydrolyzed to produce ADP and energy ]]> Wed, 12 Aug 2020 11:43:35 GMT /slideshow/genetic-polymorphism-in-drug-transport-and-drug-targets/237780983 pavithravinayak@slideshare.net(pavithravinayak) Genetic polymorphism in drug transport and drug targets. pavithravinayak Genetic polymorphism in drug transport and targets.--pharmacogenetics DRUG TRANSPORTER Two types of transporter : ATP binding Cassette (ABC) Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer. Solute Carrier (SLC) Transport varieties of solute include both charged or uncharged P-glycoprotein ATP binding cassette subfamily B member- 1 (ABCB 1) Multidrug resistance protein 1 (MDR1) Transport various molecules, including xenobiotic, across cell membrane Extensively distributed and expressed throughout the body Mechanism of Pglycoprotein Substrate bind to P-gp form the inner leaflet of the membrane ATP binds at the inner side of the protein ATP is hydrolyzed to produce ADP and energy <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pavi-drugtransportandtargets-200812114336-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Genetic polymorphism in drug transport and targets.--pharmacogenetics DRUG TRANSPORTER Two types of transporter : ATP binding Cassette (ABC) Found in ABCB, ABCD and ABCG family. Associated with multidrug resistance (MDR) of tumor cells causing treatment failure in cancer. Solute Carrier (SLC) Transport varieties of solute include both charged or uncharged P-glycoprotein ATP binding cassette subfamily B member- 1 (ABCB 1) Multidrug resistance protein 1 (MDR1) Transport various molecules, including xenobiotic, across cell membrane Extensively distributed and expressed throughout the body Mechanism of Pglycoprotein Substrate bind to P-gp form the inner leaflet of the membrane ATP binds at the inner side of the protein ATP is hydrolyzed to produce ADP and energy
Genetic polymorphism in drug transport and drug targets. from pavithra vinayak
]]> 9739 0 https://cdn.slidesharecdn.com/ss_thumbnails/pavi-drugtransportandtargets-200812114336-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Clinical pharmacokinetics and its application /slideshow/clinical-pharmacokinetics-and-its-application/237780755 pavi-cpappli-200812113415
Clinical pharmacokinetics and its application-- 1)definition 2) APPLICATIONS OF CLINICAL PHARMACOKINETICS Design of dosage regimens: a) Nomograms and Tabulations in designing dosage regimen, b) Conversion from intravenous to oral dosing, c) Determination of dose and dosing intervals, d) Drug dosing in the elderly and pediatrics and obese patients. Pharmacokinetics of Drug Interaction: a) Pharmacokinetic drug interactions b) Inhibition and Induction of Drug metabolism c) Inhibition of Biliary Excretion. Therapeutic Drug monitoring: a) Introduction b) Individualization of drug dosage regimen (Variability Genetic, Age and Weight, disease, Interacting drugs). c) Indications for TDM. Protocol for TDM. d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy. e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations Dosage adjustment in Renal and Hepatic Disease. a. Renal impairment b. Pharmacokinetic considerations c. General approach for dosage adjustment in renal disease. d. Measurement of Glomerular Filtration rate and creatinine clearance. e. Dosage adjustment for uremic patients. f. Extracorporeal removal of drugs. g. Effect of Hepatic disease on pharmacokinetics. Population Pharmacokinetics. a) Introduction to Bayesian Theory. b) Adaptive method or Dosing with feedback. c) Analysis of Population pharmacokinetic Data ]]>
Clinical pharmacokinetics and its application-- 1)definition 2) APPLICATIONS OF CLINICAL PHARMACOKINETICS Design of dosage regimens: a) Nomograms and Tabulations in designing dosage regimen, b) Conversion from intravenous to oral dosing, c) Determination of dose and dosing intervals, d) Drug dosing in the elderly and pediatrics and obese patients. Pharmacokinetics of Drug Interaction: a) Pharmacokinetic drug interactions b) Inhibition and Induction of Drug metabolism c) Inhibition of Biliary Excretion. Therapeutic Drug monitoring: a) Introduction b) Individualization of drug dosage regimen (Variability Genetic, Age and Weight, disease, Interacting drugs). c) Indications for TDM. Protocol for TDM. d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy. e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations Dosage adjustment in Renal and Hepatic Disease. a. Renal impairment b. Pharmacokinetic considerations c. General approach for dosage adjustment in renal disease. d. Measurement of Glomerular Filtration rate and creatinine clearance. e. Dosage adjustment for uremic patients. f. Extracorporeal removal of drugs. g. Effect of Hepatic disease on pharmacokinetics. Population Pharmacokinetics. a) Introduction to Bayesian Theory. b) Adaptive method or Dosing with feedback. c) Analysis of Population pharmacokinetic Data ]]> Wed, 12 Aug 2020 11:34:15 GMT /slideshow/clinical-pharmacokinetics-and-its-application/237780755 pavithravinayak@slideshare.net(pavithravinayak) Clinical pharmacokinetics and its application pavithravinayak Clinical pharmacokinetics and its application-- 1)definition 2) APPLICATIONS OF CLINICAL PHARMACOKINETICS Design of dosage regimens: a) Nomograms and Tabulations in designing dosage regimen, b) Conversion from intravenous to oral dosing, c) Determination of dose and dosing intervals, d) Drug dosing in the elderly and pediatrics and obese patients. Pharmacokinetics of Drug Interaction: a) Pharmacokinetic drug interactions b) Inhibition and Induction of Drug metabolism c) Inhibition of Biliary Excretion. Therapeutic Drug monitoring: a) Introduction b) Individualization of drug dosage regimen (Variability Genetic, Age and Weight, disease, Interacting drugs). c) Indications for TDM. Protocol for TDM. d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy. e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations Dosage adjustment in Renal and Hepatic Disease. a. Renal impairment b. Pharmacokinetic considerations c. General approach for dosage adjustment in renal disease. d. Measurement of Glomerular Filtration rate and creatinine clearance. e. Dosage adjustment for uremic patients. f. Extracorporeal removal of drugs. g. Effect of Hepatic disease on pharmacokinetics. Population Pharmacokinetics. a) Introduction to Bayesian Theory. b) Adaptive method or Dosing with feedback. c) Analysis of Population pharmacokinetic Data <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pavi-cpappli-200812113415-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Clinical pharmacokinetics and its application-- 1)definition 2) APPLICATIONS OF CLINICAL PHARMACOKINETICS Design of dosage regimens: a) Nomograms and Tabulations in designing dosage regimen, b) Conversion from intravenous to oral dosing, c) Determination of dose and dosing intervals, d) Drug dosing in the elderly and pediatrics and obese patients. Pharmacokinetics of Drug Interaction: a) Pharmacokinetic drug interactions b) Inhibition and Induction of Drug metabolism c) Inhibition of Biliary Excretion. Therapeutic Drug monitoring: a) Introduction b) Individualization of drug dosage regimen (Variability Genetic, Age and Weight, disease, Interacting drugs). c) Indications for TDM. Protocol for TDM. d) Pharmacokinetic/Pharmacodynamic Correlation in drug therapy. e) TDM of drugs used in the following disease conditions: cardiovascular disease, Seizure disorders, Psychiatric conditions, and Organ transplantations Dosage adjustment in Renal and Hepatic Disease. a. Renal impairment b. Pharmacokinetic considerations c. General approach for dosage adjustment in renal disease. d. Measurement of Glomerular Filtration rate and creatinine clearance. e. Dosage adjustment for uremic patients. f. Extracorporeal removal of drugs. g. Effect of Hepatic disease on pharmacokinetics. Population Pharmacokinetics. a) Introduction to Bayesian Theory. b) Adaptive method or Dosing with feedback. c) Analysis of Population pharmacokinetic Data
Clinical pharmacokinetics and its application from pavithra vinayak
]]> 12130 0 https://cdn.slidesharecdn.com/ss_thumbnails/pavi-cpappli-200812113415-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) /slideshow/therapeutic-drug-monitoring-for-immunosuppressive-agents-organ-transplants/237780552 paviimmunosuppressiveagents-200812112619
Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) 1)CALCINEURIN INHIBITORS i. CYCLOSPORIN/ CYCLOSPORINE ii. SIROLIMUS iii. TACROLIMUS iv. EVAROLIMUS 2) ANTIPROLIFERATIVE/ANTIMETABOLIC AGENTS, i. MYCOPHENOLATE ii. AZATHIOPRINE 3) BIOLOGICS (ANTIBODIES) i. MUROMONAB-CD3 (OKT3) ii. BASILIXIMAB iii. DACLIZUMAB iv. ALEMTUZUMAB v. ANTITHYMOCYTE GLOBULIN 4)GLUCOCORTICOIDS, clinical pharmacokinetics and therapeutic drug monitoring ----- fifth pharm D notes]]>
Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) 1)CALCINEURIN INHIBITORS i. CYCLOSPORIN/ CYCLOSPORINE ii. SIROLIMUS iii. TACROLIMUS iv. EVAROLIMUS 2) ANTIPROLIFERATIVE/ANTIMETABOLIC AGENTS, i. MYCOPHENOLATE ii. AZATHIOPRINE 3) BIOLOGICS (ANTIBODIES) i. MUROMONAB-CD3 (OKT3) ii. BASILIXIMAB iii. DACLIZUMAB iv. ALEMTUZUMAB v. ANTITHYMOCYTE GLOBULIN 4)GLUCOCORTICOIDS, clinical pharmacokinetics and therapeutic drug monitoring ----- fifth pharm D notes]]> Wed, 12 Aug 2020 11:26:19 GMT /slideshow/therapeutic-drug-monitoring-for-immunosuppressive-agents-organ-transplants/237780552 pavithravinayak@slideshare.net(pavithravinayak) Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) pavithravinayak Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) 1)CALCINEURIN INHIBITORS i. CYCLOSPORIN/ CYCLOSPORINE ii. SIROLIMUS iii. TACROLIMUS iv. EVAROLIMUS 2) ANTIPROLIFERATIVE/ANTIMETABOLIC AGENTS, i. MYCOPHENOLATE ii. AZATHIOPRINE 3) BIOLOGICS (ANTIBODIES) i. MUROMONAB-CD3 (OKT3) ii. BASILIXIMAB iii. DACLIZUMAB iv. ALEMTUZUMAB v. ANTITHYMOCYTE GLOBULIN 4)GLUCOCORTICOIDS, clinical pharmacokinetics and therapeutic drug monitoring ----- fifth pharm D notes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/paviimmunosuppressiveagents-200812112619-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) 1)CALCINEURIN INHIBITORS i. CYCLOSPORIN/ CYCLOSPORINE ii. SIROLIMUS iii. TACROLIMUS iv. EVAROLIMUS 2) ANTIPROLIFERATIVE/ANTIMETABOLIC AGENTS, i. MYCOPHENOLATE ii. AZATHIOPRINE 3) BIOLOGICS (ANTIBODIES) i. MUROMONAB-CD3 (OKT3) ii. BASILIXIMAB iii. DACLIZUMAB iv. ALEMTUZUMAB v. ANTITHYMOCYTE GLOBULIN 4)GLUCOCORTICOIDS, clinical pharmacokinetics and therapeutic drug monitoring ----- fifth pharm D notes
Therapeutic drug monitoring for immunosuppressive agents ( organ transplants) from pavithra vinayak
]]> 1954 0 https://cdn.slidesharecdn.com/ss_thumbnails/paviimmunosuppressiveagents-200812112619-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen /slideshow/conversion-from-intravenous-to-oral-dosing-design-of-dosage-regimen/237780356 pavi-conversionfromivtopo-200812111803
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes ]]>
conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes ]]> Wed, 12 Aug 2020 11:18:03 GMT /slideshow/conversion-from-intravenous-to-oral-dosing-design-of-dosage-regimen/237780356 pavithravinayak@slideshare.net(pavithravinayak) conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen pavithravinayak conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pavi-conversionfromivtopo-200812111803-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> conversion from INTRAVENOUS TO ORAL DOSING----- TYPES OF IV TO PO THERAPY CONVERSIONS: MEDICATIONS INCLUDED IN AN IV TO PO CONVERSION PROGRAM: SELECTION OF PATIENTS FOR IV TO PO THERAPY CONVERSION: design of dosage regimen--clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen from pavithra vinayak
]]> 14793 0 https://cdn.slidesharecdn.com/ss_thumbnails/pavi-conversionfromivtopo-200812111803-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Nomograms and tabulations in design of dosage regimens /slideshow/nomograms-and-tabulations-in-design-of-dosage-regimens/237780187 nomogramstabulationsindesignofdosageregimens-200812111113
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes]]>
Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes]]> Wed, 12 Aug 2020 11:11:13 GMT /slideshow/nomograms-and-tabulations-in-design-of-dosage-regimens/237780187 pavithravinayak@slideshare.net(pavithravinayak) Nomograms and tabulations in design of dosage regimens pavithravinayak Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nomogramstabulationsindesignofdosageregimens-200812111113-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Nomograms and tabulations in the design of dosage regimens --- NOMOGRAM IN UREMIC PATIENTS: NOMOGRAM FOR RELATIONSHIP BETWEEN CREATININE CLEARANCE AND ELIMINATION RATE CONSTANT FOR FOUR DRUGS clinical pharmacokinetics and therapeutic drug monitoring ---fifth PharmD notes
Nomograms and tabulations in design of dosage regimens from pavithra vinayak
]]> 16854 0 https://cdn.slidesharecdn.com/ss_thumbnails/nomogramstabulationsindesignofdosageregimens-200812111113-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Adaptive method OR dosing with feedback /pavithravinayak/adaptive-method-or-dosing-with-feedback adaptivemethodp-200812110251
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes]]>
adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes]]> Wed, 12 Aug 2020 11:02:51 GMT /pavithravinayak/adaptive-method-or-dosing-with-feedback pavithravinayak@slideshare.net(pavithravinayak) Adaptive method OR dosing with feedback pavithravinayak adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/adaptivemethodp-200812110251-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> adaptive methods are doing with feedback in population pharmacokinetics---- clinical pharmacokinetics and therapeutic drug monitoring-- fifth pharm D notes
Adaptive method OR dosing with feedback from pavithra vinayak
]]> 5926 0 https://cdn.slidesharecdn.com/ss_thumbnails/adaptivemethodp-200812110251-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Bayesian theory /slideshow/bayesian-theory/237779857 bayesiantheory-pavi-200812105609
Bayesian theory in population pharmacokinetics-- 1) INTRODUCTION TO BAYESIAN THEORY 2)BAYESIAN PROBABILITY TO DOSING OF DRUGS 3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS: therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes]]>
Bayesian theory in population pharmacokinetics-- 1) INTRODUCTION TO BAYESIAN THEORY 2)BAYESIAN PROBABILITY TO DOSING OF DRUGS 3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS: therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes]]> Wed, 12 Aug 2020 10:56:09 GMT /slideshow/bayesian-theory/237779857 pavithravinayak@slideshare.net(pavithravinayak) Bayesian theory pavithravinayak Bayesian theory in population pharmacokinetics-- 1) INTRODUCTION TO BAYESIAN THEORY 2)BAYESIAN PROBABILITY TO DOSING OF DRUGS 3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS: therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/bayesiantheory-pavi-200812105609-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Bayesian theory in population pharmacokinetics-- 1) INTRODUCTION TO BAYESIAN THEORY 2)BAYESIAN PROBABILITY TO DOSING OF DRUGS 3)APPLICATIONS AND USES OF BAYESIAN THEORY IN APPLIED PHARMACOKINETICS: therapeutic drug monitoring and clinical pharmacokinetics-fifth pharm d notes
Bayesian theory from pavithra vinayak
]]> 10959 0 https://cdn.slidesharecdn.com/ss_thumbnails/bayesiantheory-pavi-200812105609-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 protocol writing in clinical research /slideshow/protocol-writing-in-clinical-research/232704743 pavi-protocolwriting-200427100007
protocol designing in clinical research - introduction, objectives, contents .....]]>
protocol designing in clinical research - introduction, objectives, contents .....]]> Mon, 27 Apr 2020 10:00:06 GMT /slideshow/protocol-writing-in-clinical-research/232704743 pavithravinayak@slideshare.net(pavithravinayak) protocol writing in clinical research pavithravinayak protocol designing in clinical research - introduction, objectives, contents ..... <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pavi-protocolwriting-200427100007-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> protocol designing in clinical research - introduction, objectives, contents .....
protocol writing in clinical research from pavithra vinayak
]]> 5871 0 https://cdn.slidesharecdn.com/ss_thumbnails/pavi-protocolwriting-200427100007-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Antidepressants -pharmacology /slideshow/antidepressants-pharmacology-108523137/108523137 antidepressants2-180803200906
depression ,symptoms, mechanism of depression ,classification of antidepressants , tri cyclic anti depressants and its pharmacological actions ,acute poisoning and treatment]]>
depression ,symptoms, mechanism of depression ,classification of antidepressants , tri cyclic anti depressants and its pharmacological actions ,acute poisoning and treatment]]> Fri, 03 Aug 2018 20:09:06 GMT /slideshow/antidepressants-pharmacology-108523137/108523137 pavithravinayak@slideshare.net(pavithravinayak) Antidepressants -pharmacology pavithravinayak depression ,symptoms, mechanism of depression ,classification of antidepressants , tri cyclic anti depressants and its pharmacological actions ,acute poisoning and treatment <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/antidepressants2-180803200906-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> depression ,symptoms, mechanism of depression ,classification of antidepressants , tri cyclic anti depressants and its pharmacological actions ,acute poisoning and treatment
Antidepressants -pharmacology from pavithra vinayak
]]> 12739 5 https://cdn.slidesharecdn.com/ss_thumbnails/antidepressants2-180803200906-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Anticholinergic drugs - pharmacology /slideshow/anticholinergic-drugs-pharmacology/108522718 anticholinergicdrugs-180803200521
introduction ,classification of cholinergic receptor ,and its function ,anti cholinergic agents -atropine and its pharmacology ,semi synthetic and synthetic atropine substitutes]]>
introduction ,classification of cholinergic receptor ,and its function ,anti cholinergic agents -atropine and its pharmacology ,semi synthetic and synthetic atropine substitutes]]> Fri, 03 Aug 2018 20:05:21 GMT /slideshow/anticholinergic-drugs-pharmacology/108522718 pavithravinayak@slideshare.net(pavithravinayak) Anticholinergic drugs - pharmacology pavithravinayak introduction ,classification of cholinergic receptor ,and its function ,anti cholinergic agents -atropine and its pharmacology ,semi synthetic and synthetic atropine substitutes <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/anticholinergicdrugs-180803200521-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> introduction ,classification of cholinergic receptor ,and its function ,anti cholinergic agents -atropine and its pharmacology ,semi synthetic and synthetic atropine substitutes
Anticholinergic drugs - pharmacology from pavithra vinayak
]]> 9642 5 https://cdn.slidesharecdn.com/ss_thumbnails/anticholinergicdrugs-180803200521-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Antianginals - pharmacology /slideshow/antianginals-pharmacology/108522286 antianginals-180803200129
principle action of drugs,types of angina classification of drugs ,nitrates,calcium channel blockers pharmacological actions ,combination therapy and its sid effects]]>
principle action of drugs,types of angina classification of drugs ,nitrates,calcium channel blockers pharmacological actions ,combination therapy and its sid effects]]> Fri, 03 Aug 2018 20:01:29 GMT /slideshow/antianginals-pharmacology/108522286 pavithravinayak@slideshare.net(pavithravinayak) Antianginals - pharmacology pavithravinayak principle action of drugs,types of angina classification of drugs ,nitrates,calcium channel blockers pharmacological actions ,combination therapy and its sid effects <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/antianginals-180803200129-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> principle action of drugs,types of angina classification of drugs ,nitrates,calcium channel blockers pharmacological actions ,combination therapy and its sid effects
Antianginals - pharmacology from pavithra vinayak
]]> 1977 2 https://cdn.slidesharecdn.com/ss_thumbnails/antianginals-180803200129-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Alpha blockers class /slideshow/alpha-blockers-class/108521874 alphablockers-class-180803195735
classification of alpha blockers, general effects of blockers ,and its pharmacological actions, drugs with therapeutic uses and its side effects]]>
classification of alpha blockers, general effects of blockers ,and its pharmacological actions, drugs with therapeutic uses and its side effects]]> Fri, 03 Aug 2018 19:57:35 GMT /slideshow/alpha-blockers-class/108521874 pavithravinayak@slideshare.net(pavithravinayak) Alpha blockers class pavithravinayak classification of alpha blockers, general effects of blockers ,and its pharmacological actions, drugs with therapeutic uses and its side effects <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/alphablockers-class-180803195735-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> classification of alpha blockers, general effects of blockers ,and its pharmacological actions, drugs with therapeutic uses and its side effects
Alpha blockers class from pavithra vinayak
]]> 1350 6 https://cdn.slidesharecdn.com/ss_thumbnails/alphablockers-class-180803195735-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 03. adrenergic drugs /slideshow/03-adrenergic-drugs/108521465 03-180803195337
anatomy of ans ,sns, chemical mediators , classification of receptors ,agonist and antagonist andits pharmacological effects and its therapeutic uses]]>
anatomy of ans ,sns, chemical mediators , classification of receptors ,agonist and antagonist andits pharmacological effects and its therapeutic uses]]> Fri, 03 Aug 2018 19:53:36 GMT /slideshow/03-adrenergic-drugs/108521465 pavithravinayak@slideshare.net(pavithravinayak) 03. adrenergic drugs pavithravinayak anatomy of ans ,sns, chemical mediators , classification of receptors ,agonist and antagonist andits pharmacological effects and its therapeutic uses <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/03-180803195337-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> anatomy of ans ,sns, chemical mediators , classification of receptors ,agonist and antagonist andits pharmacological effects and its therapeutic uses
03. adrenergic drugs from pavithra vinayak
]]> 434 2 https://cdn.slidesharecdn.com/ss_thumbnails/03-180803195337-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Vasomotor reversal of dale /slideshow/vasomotor-reversal-of-dale/108521200 vasomotorreversalofdale-180803195109
dales vasomotor reversal and rereversal by using alpha and beta blockers]]>
dales vasomotor reversal and rereversal by using alpha and beta blockers]]> Fri, 03 Aug 2018 19:51:08 GMT /slideshow/vasomotor-reversal-of-dale/108521200 pavithravinayak@slideshare.net(pavithravinayak) Vasomotor reversal of dale pavithravinayak dales vasomotor reversal and rereversal by using alpha and beta blockers <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vasomotorreversalofdale-180803195109-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> dales vasomotor reversal and rereversal by using alpha and beta blockers
Vasomotor reversal of dale from pavithra vinayak
]]> 43638 6 https://cdn.slidesharecdn.com/ss_thumbnails/vasomotorreversalofdale-180803195109-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Alcohol class /slideshow/alcohol-class-108520890/108520890 alcoholclass-180803194820
pharmacological actions of alcohol, effects of alcohol consumption -acute and chronic and its pharmacokinetics]]>
pharmacological actions of alcohol, effects of alcohol consumption -acute and chronic and its pharmacokinetics]]> Fri, 03 Aug 2018 19:48:20 GMT /slideshow/alcohol-class-108520890/108520890 pavithravinayak@slideshare.net(pavithravinayak) Alcohol class pavithravinayak pharmacological actions of alcohol, effects of alcohol consumption -acute and chronic and its pharmacokinetics <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/alcoholclass-180803194820-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> pharmacological actions of alcohol, effects of alcohol consumption -acute and chronic and its pharmacokinetics
Alcohol class from pavithra vinayak
]]> 369 6 https://cdn.slidesharecdn.com/ss_thumbnails/alcoholclass-180803194820-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Gene expression /slideshow/gene-expression-108235926/108235926 geneexpression-180801141614
regulation ,steps,prokaryotes and eukaryotes ,operon ,check points,elements for gene expression]]>
regulation ,steps,prokaryotes and eukaryotes ,operon ,check points,elements for gene expression]]> Wed, 01 Aug 2018 14:16:13 GMT /slideshow/gene-expression-108235926/108235926 pavithravinayak@slideshare.net(pavithravinayak) Gene expression pavithravinayak regulation ,steps,prokaryotes and eukaryotes ,operon ,check points,elements for gene expression <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/geneexpression-180801141614-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> regulation ,steps,prokaryotes and eukaryotes ,operon ,check points,elements for gene expression
Gene expression from pavithra vinayak
]]> 4043 2 https://cdn.slidesharecdn.com/ss_thumbnails/geneexpression-180801141614-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Glaucoma /slideshow/glaucoma-108235545/108235545 glaucoma-180801141206
definition ,classification,symptoms and treatment]]>
definition ,classification,symptoms and treatment]]> Wed, 01 Aug 2018 14:12:06 GMT /slideshow/glaucoma-108235545/108235545 pavithravinayak@slideshare.net(pavithravinayak) Glaucoma pavithravinayak definition ,classification,symptoms and treatment <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/glaucoma-180801141206-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> definition ,classification,symptoms and treatment
Glaucoma from pavithra vinayak
]]> 790 2 https://cdn.slidesharecdn.com/ss_thumbnails/glaucoma-180801141206-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Congestive heartfailure /slideshow/congestive-heartfailure-108235387/108235387 congestiveheartfailure-180801141024
causes and pharmacotherapy]]>
causes and pharmacotherapy]]> Wed, 01 Aug 2018 14:10:24 GMT /slideshow/congestive-heartfailure-108235387/108235387 pavithravinayak@slideshare.net(pavithravinayak) Congestive heartfailure pavithravinayak causes and pharmacotherapy <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/congestiveheartfailure-180801141024-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> causes and pharmacotherapy
Congestive heartfailure from pavithra vinayak
]]> 563 6 https://cdn.slidesharecdn.com/ss_thumbnails/congestiveheartfailure-180801141024-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://public.slidesharecdn.com/v2/images/profile-picture.png https://cdn.slidesharecdn.com/ss_thumbnails/pavi-gfrestimation-200812120447-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/mesurement-of-gfr-and-creatinine-clearence/237781500 Mesurement of GFR and ... https://cdn.slidesharecdn.com/ss_thumbnails/pavi-effectofliverdiseaseonpkfactors-200812115918-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/effect-of-liver-disease-on-pharmacokinetics/237781348 Effect of liver disea... https://cdn.slidesharecdn.com/ss_thumbnails/pavi-drugtransportandtargets-200812114336-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/genetic-polymorphism-in-drug-transport-and-drug-targets/237780983 Genetic polymorphism i...